Ingenix, a Warsaw-based healthcare AI startup, has successfully raised €9 million in seed funding to develop groundbreaking technology that simulates clinical trials through advanced AI modeling. This funding round was led by Inovo.vc, with additional investments from OTB Ventures and the International Finance Corporation (IFC). Inovo shared the announcement with AIN in a press release.
About Ingenix
-
Founded by Piotr Surma and Adam Dancewicz, who previously established the AI-based startup Applica (acquired by Snowflake in 2022), Ingenix is set to transform the pharmaceutical landscape.
-
The company’s platform can accurately simulate drug trials from a molecular level up to the population level, enabling granular predictions of clinical outcomes and adverse events.
-
This technology addresses a critical need in the pharmaceutical industry, which currently invests around $50 billion annually in clinical trials, yet 90% of pilot drugs do not secure regulatory approval.
“The intricacies of human biology make the development of any AI technology incredibly complex. However, with the support of our new investors, we are excited to fulfill the potential of Ingenix and change the way clinical trials are conducted,” Co-Founder and CEO Piotr Surma comments.
Investment Details
-
The fresh investment was made through Inovo Fund 3, which aims to invest over €100 million in outstanding founders from Central and Eastern Europe. Inovo.vc has previously invested in notable healthcare and AI startups, including Infermedica, Jutro Medical, and uPacjenta.
-
The investment was also supported by OTB Fund 2, which closed oversubscribed in 2024 at $185 million. The fund is backed by the NATO Innovation Fund and the European Investment Fund. OTB Ventures focuses on Series A and late seed rounds for deep tech startups, supporting pioneering technologies in various sectors.
-
A member of the World Bank Group, the IFC joined the funding round. Their investment in Ingenix aligns with IFC’s digital health strategy, supporting advanced generative AI for clinical research and ensuring that innovations benefit developing regions.
With fresh funds, Ingenix aims to further enhance the efficiency of clinical trial processes, reduce drug development timelines, and bring innovative therapies to market more quickly and cost-effectively.
